Skip to main content
. 2023 Aug 7;21:531. doi: 10.1186/s12967-023-04322-0

Table 1.

The baseline characteristics of participants

RC T1(< 18.50 mg/dL) T2(18.50–25.60 mg/dL) T3(> 25.60 mg/dL) P-value
Participants 194 196 200
Age(years) 31.61 ± 3.67 32.22 ± 3.60 32.35 ± 4.07 0.116
Pre-pregnancy BMI (kg/m2) 21.05 ± 2.68 21.80 ± 3.49 23.23 ± 3.87  < 0.001
GGT(IU/L) 11.00 (9.25–14.00) 11.00 (9.00–14.00) 13.00 (10.00–18.00)  < 0.001
TC (mg/dL) 161.24 ± 22.28 172.31 ± 25.41 184.68 ± 28.33  < 0.001
TG (mg/dL) 76.42 ± 12.71 109.54 ± 10.22 169.55 ± 44.69  < 0.001
HDL-c(mg/dL) 66.51 ± 11.91 65.96 ± 13.81 62.34 ± 14.42 0.004
LDL-c(mg/dL) 79.46 ± 19.13 84.44 ± 20.38 88.05 ± 24.59  < 0.001
HLR 0.90 ± 0.32 0.83 ± 0.30 0.77 ± 0.31
RC (mg/dL) 15.27 ± 2.52 21.90 ± 2.04 34.29 ± 9.79  < 0.001
Adipokines(ng/mL) 6402.45 (3847.80–9978.28) 5482.90 (3196.80–8228.60) 3739.35 (2062.43–6010.28)  < 0.001
AST(IU/L) 16.00 (14.00–18.75) 16.00 (14.00–19.00) 17.00 (14.00–21.00) 0.085
ALT(IU/L) 11.00 (8.00–14.00) 11.00 (8.00–15.00) 11.50 (8.00–18.00) 0.068
FPG (mg/dL) 75.84 ± 8.95 77.14 ± 9.96 78.09 ± 10.17 0.058
Insulin(μIU/mL) 6.70 (4.32–10.07) 7.95 (5.30–10.93) 10.30 (7.30–15.07)  < 0.001
HOMA-IR 1.30 (0.80–1.90) 1.50 (0.90–2.20) 2.00 (1.30–2.82)  < 0.001
Nulliparity(n,%) 0.069
 No 115 (59.28%) 98 (50.00%) 97 (48.50%)
 Yes 79 (40.72%) 98 (50.00%) 103 (51.50%)
Hepatic steatosis(n,%)  < 0.001
 Grade 0 167 (86.08%) 171 (87.24%) 141 (70.50%)
 Grade 1 27 (13.92%) 19 (9.69%) 39 (19.50%)
 Grade 2 0 (0.00%) 5 (2.55%) 13 (6.50%)
 Grade 3 0 (0.00%) 1 (0.51%) 7 (3.50%)

Continuous variables were summarized as mean (SD) or medians (quartile interval); categorical variables were displayed as a percentage (%)

RC remnant cholesterol, BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, HDL-c high-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, LDL-c low-density lipid cholesterol, HLR high-density lipoprotein cholesterol to low-density lipid cholesterol ratio, FPG fasting plasma glucose, HOMA-IR homeostasis model assessment-insulin resistance